Electra Therapeutics (NASDAQ:ETRA) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Electra Therapeutics (NASDAQ:ETRA) in a report issued on Thursday morning, Marketbeat.com reports. The firm issued an overweight rating and a $36.00 target price on the stock.

ETRA has been the subject of a number of other research reports. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. Jefferies Financial Group started coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective on the stock. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. TD Cowen began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating on the stock. Finally, Evercore began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an “outperform” rating and a $36.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $34.67.

Electra Therapeutics Stock Performance

Electra Therapeutics stock opened at $8.71 on Thursday. Electra Therapeutics has a fifty-two week low of $8.50 and a fifty-two week high of $15.50.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc bought 1,333,333 shares of the stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Carl Gordon acquired 1,333,333 shares of the stock in a transaction on Monday, September 21st. The stock was bought at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.